Travel Grant (2026), Japan & South Korea, Nordic Health Summit, 23 – 30 April 2026

Purpose and goal

The purpose is to participate in the Nordic Health Summit 2026 in Tokyo and Seoul to connect with Asian investors and pharmaceutical companies. The goal is to secure funding from Asian venture capital firms and establish co-development and partnering agreements with Japanese and Korean pharmaceutical companies to accelerate the clinical development and future commercialization of ATR-258 for the treatment of type 2 diabetes, obesity, and sarcopenia.

Expected effects and result

Expected results include new investor relationships with Asian venture capital firms, partnership discussions with Japanese and Korean pharmaceutical companies, and refined regulatory and commercial strategies for the Asian market. Expected effects are accelerated Phase II development of ATR-258 through secured funding, a strengthened international network supporting future market entry in Asia, and faster access to treatments for type 2 diabetes, obesity, and sarcopenia.

Planned approach and implementation

Two representatives from Atrogi AB will attend the Nordic Health Summit 2026 in Tokyo and Seoul. Prior to the summit, we will identify and prioritize target investors and pharmaceutical companies for scheduled meetings. During the summit, we will participate in partnering sessions, deliver presentations on ATR-258, and conduct one-on-one meetings with potential partners and investors. Post-summit, we will follow up on all leads to advance partnership and funding discussions.